Global Transmucosal Drugs Market to Reach ~USD 28 Billion by 2032 | DelveInsight

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from 2025 to 2032 include the rising adoption of these drugs, along with growing research and development efforts and collaborations among major industry players.

LAS VEGAS, Feb. 18, 2025 /PRNewswire/ -- DelveInsight's Transmucosal Drugs Market Insights report provides the current and forecast market analysis, individual leading transmucosal drugs companies' market shares, challenges, transmucosal drugs market drivers, barriers, trends, and key market transmucosal drugs companies in the market.

Key Takeaways from the Transmucosal Drugs Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global transmucosal drugs market during the forecast period. 
• In the product segment of the transmucosal drugs market, the tablet category had a significant revenue share in the transmucosal drugs market in 2024.
• Notable transmucosal drugs companies such as Teva Pharmaceutical Industries Ltd, Indivior PLC, GSK plc, Emergent BioSolutions Inc., Bayer AG, AbbVie Inc., Organon group of companies, Pfizer Inc., Prestige Consumer Healthcare, Inc., Merck & Co., Inc., Aquestive Therapeutics, Inc., Ferring, Novartis AG, Adalvo Limited, Sumitomo Pharma Co., Ltd., ZIM LABORATORIES LIMITED, BioXcel Therapeutics, Inc., BIAL, Almac Group, Boehringer Ingelheim International GmbH, and several others, are currently operating in the transmucosal drugs market.
• In March 2024, BIAL launched KYNMOBI (apomorphine hydrochloride) in Germany. KYNMOBI is the sublingual film for the intermittent treatment of OFF episodes in adult patients with Parkinson's disease.
• In March 2024, Tonix Pharmaceuticals announced its collaboration with Almac Pharma Services for the launch and commercialization of TonmyaTM (cyclobenzaprine HCl sublingual tablets) in the U.S. Tonmya is a centrally acting opioid analgesic for the treatment of fibromyalgia.

To read more about the latest highlights related to the transmucosal drugs market, get a snapshot of the key highlights entailed in the Global Transmucosal Drugs Market Report

Transmucosal Drugs Overview

Transmucosal drugs are a category of medications designed to be absorbed through mucous membranes, such as those found in the mouth, nasal passages, or gastrointestinal tract. These drugs are typically formulated as lozenges, films, sprays, or tablets that dissolve upon contact with mucosal surfaces. The primary advantage of transmucosal drug delivery is its ability to bypass the digestive system, leading to faster absorption and onset of action compared to oral administration. This can be particularly beneficial for drugs that are poorly absorbed through the gastrointestinal tract or those that need to act quickly, such as pain relief medications or treatments for acute conditions.

The transmucosal route can offer increased bioavailability, as the drug is absorbed directly into the bloodstream through the mucosal membranes, often avoiding first-pass metabolism in the liver. This can reduce the required dosage and minimize side effects. Additionally, transmucosal drug delivery systems are typically non-invasive and convenient for patients, making them an attractive option for chronic treatments or for populations that may struggle with traditional oral medications, such as pediatric or geriatric patients. However, this form of drug delivery requires careful formulation to ensure proper drug release, stability, and patient adherence.

Transmucosal Drugs Market Insights

North America is projected to hold the largest share of the transmucosal drugs market in the coming years compared to other regions. This growth is primarily driven by the increasing prevalence of chronic conditions such as hypertension and neurological diseases, alongside the growing research and development efforts by major industry players. Notable market players are focusing on creating innovative treatments for neurological disorders. 

For example, in April 2022, BioXcel Therapeutics, Inc. received approval from the U.S. Food and Drug Administration (FDA) for IGALMITM (dexmedetomidine) sublingual film to treat acute agitation linked to schizophrenia or bipolar I or II disorder in adults. These advancements in drug development are expected to further boost market expansion in North America. 

Thus, the rising incidence of chronic diseases and the introduction of new products by key players are key drivers of the transmucosal drugs market growth in the region.

To know more about why North America is leading the market growth in the transmucosal drugs market, get a snapshot of the Transmucosal Drugs Market Outlook 

Transmucosal Drugs Market Dynamics

The transmucosal drugs market has been witnessing significant growth, driven by its ability to offer an effective and less invasive alternative to conventional drug administration methods. Transmucosal delivery involves the absorption of therapeutic agents through mucous membranes, such as the nasal, buccal, or sublingual areas. This method bypasses the digestive system, allowing for faster onset of action and enhanced bioavailability, particularly for drugs that are poorly absorbed through the gastrointestinal tract. The demand for this delivery method is particularly prominent in the management of conditions that require rapid symptom relief, such as acute pain, migraine, and anxiety disorders.

Technological advancements play a key role in the dynamics of the transmucosal drugs market. Innovations such as nanoparticles, liposomes, and microneedles are improving the efficiency and accuracy of drug delivery systems. For example, the development of nasal sprays and sublingual tablets has revolutionized the administration of both peptide and non-peptide drugs. These technologies not only enhance drug absorption but also help in reducing side effects by targeting specific areas in the body. Moreover, the ease of administration and the patient-friendly nature of these systems have made them a preferred choice, particularly in the pediatric and geriatric populations.

Additionally, market growth is supported by an increasing demand for personalized medicine. As treatments become more tailored to individual patient needs, transmucosal delivery systems provide an effective way to fine-tune drug doses and achieve optimal therapeutic outcomes. For instance, the ability to deliver drugs directly into the bloodstream through the mucosal membranes allows for better control over drug release rates, which is particularly important for chronic conditions requiring long-term management. This shift towards more personalized treatments has been further augmented by the rise of digital health technologies, such as remote monitoring tools that ensure patients adhere to their prescribed treatments.

Despite the many advantages, the transmucosal drugs market also faces challenges. The high cost of research and development, coupled with regulatory hurdles for new drug delivery systems, can impede market expansion. Furthermore, the potential for irritation or infection at the site of drug administration, particularly for chronic use, remains a concern. As a result, manufacturers must invest in developing more user-friendly, efficient, and safer products to maintain consumer trust. Overall, while the transmucosal drugs market shows great promise, the need for continuous innovation and rigorous safety standards will be critical for its sustained growth.

Get a sneak peek at the transmucosal drugs market dynamics @ Transmucosal Drugs Market Dynamics Analysis

Transmucosal Drugs Market Assessment

• Transmucosal Drugs Market Segmentation
• Transmucosal Drugs Market Segmentation By Product: Nasal Spray, Tablet, Film, and Others
• Transmucosal Drugs Market Segmentation By Route of Administration: Oral, Nasal, Sublingual, Buccal, and Others
• Transmucosal Drugs Market Segmentation By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
• Transmucosal Drugs Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Which MedTech key players in the transmucosal drugs market are set to emerge as the trendsetter explore @ Transmucosal Drugs Companies 

Table of Contents 

Interested in knowing the transmucosal drugs market by 2032? Click to get a snapshot of the Transmucosal Drugs Market Trends

Related Reports

Transmucosal Drug Delivery Devices Market

Transmucosal Drug Delivery Devices Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key transmucosal drug delivery devices companies, including 3M, Cephalon Inc., Biopharmaceutical, Antares Pharma, Teva Pharmaceutical Industries Ltd., Slan Medicinal Holdings Ltd, MMB Healthcare, LLC, BioDelivery Sciences International Inc., Mylan N.V., among others.

Hypertension Market

Hypertension Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hypertension companies, including JeniVision, Inc., AI Therapeutics, Inc., Apnimed, AstraZeneca, Aerovate Therapeutics, Merck Sharp & Dohme LLC, AbbVie, Alnylam Pharmaceuticals, Gossamer Bio Inc., Insmed Incorporated, Actelion, Boehringer Ingelheim, Acceleron Pharma, Bayer, Perfuse Therapeutics, Inc., KBP Biosciences, Novartis, Gmax Biopharm LLC, United Therapeutics, Tarsier Pharma, among others.

Hypertension Pipeline

Hypertension Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hypertension companies, including Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision, Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics, Inc., Aadi Bioscience, Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma, LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio, Inc., Santen Pharmaceutical,  VivaVision Biotech, Mitsubishi Chemical Group Corporation., Idorsia Pharmaceuticals, United Therapeutics Corporation, VIVUS LLC., PhaseBio Pharmaceuticals, Vascular Biosciences, CAR peptide, Liquidia Corporation, Centessa Pharmaceuticals, Claritas Pharmaceuticals, Halo Biosciences, PulmoSIM Therapeutics, Keros Therapeutics, among others.

Pulmonary Arterial Hypertension Market

Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pulmonary arterial hypertension companies including Merck, United Therapeutics, Liquida Technologies, Tenax Therapeutics, Respira Therapeutics, Gossamer Bio, Pharmosa Biopharma, Aerovate Therapeutics, Insmed, Novartis, Cumberland Pharmaceuticals, Enzyvant Therapeutics, AstraZeneca, Cereno Scientific, PhaseBio Pharmaceutical, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

Contact Us
Shruti Thakur
[email protected]  
+14699457679
https://www.delveinsight.com/medical-devices   

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP